Global Impact of Optimal Implementation of Guideline-Directed Medical Therapy in Heart Failure

被引:0
|
作者
Tang, Amber B. [1 ]
Ziaeian, Boback [2 ]
Butler, Javed [3 ,4 ]
Yancy, Clyde W. [5 ]
Fonarow, Gregg C. [2 ]
机构
[1] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA
[2] Univ Calif Los Angeles, Div Cardiol, 10833 LeConte Ave, Los Angeles, CA 90095 USA
[3] Baylor Scott & White Res Inst, Dallas, TX USA
[4] Univ Mississippi, Jackson, MS USA
[5] Northwestern Univ, Feinberg Sch Med, Div Cardiol, Chicago, IL USA
关键词
D O I
10.1001/jamacardio.2024.3023
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
ImportanceGuideline-directed medical therapy (GDMT) remains underutilized on a global level, with significant disparities in access to treatment worldwide. The potential global benefits of quadruple therapy on patients with heart failure with reduced ejection fraction (HFrEF) have not yet been estimated. ObjectiveTo assess the projected population-level benefit of optimal GDMT use globally among patients with HFrEF. Design, Setting, and ParticipantsEstimates for HFrEF prevalence, contraindications to GDMT, treatment rates, and the number needed to treat for all-cause mortality at 12 months were derived from previously published sources. Potential lives saved from optimal implementation of quadruple therapy among patients with HFrEF was calculated globally and a sensitivity analysis was conducted to account for uncertainty in the existing data. Main Outcomes and MeasuresAll-cause mortality. ResultsOf an estimated 28.89 million people with HFrEF worldwide, there were 8 235 063 (95% CI, 6 296 020-10 762 972) potentially eligible for but not receiving beta-blockers, 20 387 000 (95% CI, 15 867 004-26 184 996) eligible for but not receiving angiotensin receptor-neprilysin inhibitors, 12 223 700 (95% CI, 9 376 895-15 924 973) eligible for but not receiving mineralocorticoid receptor antagonists, and 21 229 170 (95% CI, 16 537 400-27 242 688) eligible for but not receiving sodium glucose cotransporter-2 inhibitors. Optimal implementation of quadruple GDMT could potentially prevent 1 188 277 (95% CI, 767 933-1 914 561) deaths over 12 months. A large proportion of deaths averted were projected in Southeast Asia, Eastern Mediterranean and Africa, and the Western Pacific regions. Conclusions and RelevanceImprovement in use of GDMT could result in substantial mortality benefits on a global scale. Significant heterogeneity also exists across regions, which warrants additional study with interventions tailored to country-level differences for optimization of GDMT worldwide.
引用
收藏
页码:1154 / 1158
页数:5
相关论文
共 50 条
  • [21] Price and Affordability of Guideline-Directed Medical Therapy for Heart Failure in Venezuela
    Gebran, Karim
    Gomes, Diana De Oliveira
    Bacci, Maria
    Pascareli, Gabriela Lombardo
    CIRCULATION, 2024, 150
  • [22] Identifying Predictors of Timing to Guideline-Directed Medical Therapy for Medical Beneficiaries With Heart Failure
    Chiang, Melody
    Kim, Dennie
    Cascino, Thomas
    Hou, Hechuan
    Hawkins, Robert
    Funk, Kylee
    Aaronson, Keith D.
    Cabrera, Lourdes
    Likosky, Donald S.
    McCullough, Jeffrey
    CIRCULATION, 2023, 148
  • [23] Optimal Guideline-Directed Medical Therapy for Patients With Stable Ischemic Heart Disease
    Shah, Rahman
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (24) : 2861 - 2862
  • [24] Guideline-Directed Medical Therapy in Heart Failure The Treatment Is Not Worse Than the Disease
    Ambardekar, Amrut, V
    El Rafei, Abdelghani
    JACC-HEART FAILURE, 2023, 11 (04) : 437 - 439
  • [25] Diversity in heart failure management: Quo Vadis, guideline-directed medical therapy?
    Meguro, Tomomi
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2024, 415
  • [26] The role of discharge checklist in guideline-directed medical therapy for heart failure patients
    Rismiati, Helsi
    Lee, Kyu-Sun
    Kang, Jeehoon
    Cho, Hyun-Jai
    Lee, Hae-Young
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2023, 38 (02): : 195 - +
  • [27] Guideline-Directed Medical Therapy in Females with Heart Failure with Reduced Ejection Fraction
    Anubha Agarwal
    Sanne A. E. Peters
    Chanchal Chandramouli
    Carolyn S. P. Lam
    Gemma A. Figtree
    Clare Arnott
    Current Heart Failure Reports, 2021, 18 : 284 - 289
  • [28] Use of guideline-directed medical therapy in women hospitalised for decompensated heart failure
    Mihelcic, G.
    Furlan, T.
    Leskovar, B.
    EUROPEAN JOURNAL OF HEART FAILURE, 2024, 26 : 413 - 413
  • [29] Guideline-Directed Medical Therapy for the Treatment of Heart Failure with Reduced Ejection Fraction
    Jay Patel
    Negin Rassekh
    Gregg C. Fonarow
    Prakash Deedwania
    Farooq H. Sheikh
    Ali Ahmed
    Phillip H. Lam
    Drugs, 2023, 83 : 747 - 759
  • [30] Guideline-Directed Medical Therapy Clinics A Call to Action for the Heart Failure Team
    O'Connor, Christopher M.
    JACC-HEART FAILURE, 2019, 7 (05) : 442 - 443